The roles of the estrogen receptor signaling pathway in endocrine agents for breast cancer in postmenopausal women and of vandetanib in treating patients with advanced hereditary medullary thyroid cancer are among the topics from the August issue of Community Oncology that are discussed by Dr. David H. Henry.